search
Back to results

Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery (PACMAN)

Primary Purpose

Major Non-cardiac Surgery

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Dexamethasone
Placebos
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Non-cardiac Surgery

Eligibility Criteria

50 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 65 years Or Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 50 years and presenting one of the following criteria

  • Presence of a defined risk factor for cardiac or respiratory disease (exercise tolerance equivalent to 6 metabolic equivalents or less)
  • Medical history of stroke
  • Moderate to severe renal impairment (clearance of creatinine ≤ 30 mll/L)
  • Active smoking
  • Averaged observed blood losses over 500 ml
  • Emergency surgery

Exclusion Criteria:

  • Pregnant women, Minors, Adults under guardianship or trusteeship
  • Treatment with systemic corticosteroids at a dose > 5 mg.day-1 of equivalent prednisolone in the previous 3 months
  • Patients with chronic renal failure (clearance of creatinine < 10 ml/min)
  • Patients for which death is deemed imminent and inevitable or patients with an underlying disease process with a life expectancy of less than 1 month
  • Patient with preoperative shock (defined by the need for vasoactive drugs before surgery)
  • Acute Pulmonary edema in the last 7 days
  • Active bacterial or viral infection
  • Allergy to the intravenous formulation of dexamethasone
  • Uncontrolled psychotic disorder (acute or chronical)

Sites / Locations

  • CHU Angers
  • CHU La Cavale Blanche
  • Hôpital Estaing, CHU de Clermont Ferrand
  • Hôpital Beaujon
  • CHD Vendée
  • Centre Hospitalier Du Mans
  • Hôpital Claude Huriez
  • Hopital Edouard Herriot
  • Institut Paoli Calmettes
  • Hôpital Timone
  • Hôpital Nord
  • Hôpital Saint-Eloi
  • Clinique Jules Verne
  • Le Confluent
  • Hotel Dieu Nantes
  • Hôpital Laennec
  • C.R.L.C.C. Nantes Atlantique
  • Hôpital Saint Antoine
  • Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand Widal
  • CHU Lyon Sud
  • CHU de Poitiers
  • Ch Quimper
  • Hôpital Pontchaillou
  • CHU de Rouen
  • CHU Saint Etienne
  • Nouvel Hôpital Civil
  • CHU de Toulouse
  • CH Valenciennes
  • Institut Gustave Roussy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Dexamethasone

placebo

Arm Description

Standard cares plus postoperative administrations of glucocorticoid

Standard cares plus postoperative administrations of placebo

Outcomes

Primary Outcome Measures

Composite outcome at least one item among the following:-Postoperative sepsis, severe sepsis, septic shock-Postoperative pulmonary complication: pneumonia, need for invasive and/or noninvasive ventilation for respiratory failure-All-cause mortality

Secondary Outcome Measures

All cause mortality
Hospital free days
Rate of patients with post operative sepsis
Postoperative intubation rate for respiratory failure
Postoperative respiratory failure requiring invasive ventilation
Rate of patients with postoperative respiratory failure requiring non-invasive ventilation
Surgical complications
The Clavien-Dindo classification
Duration of hospitalization
Rate of unplanned hospitalization in intensive care unit
Rate of patients developing postoperative organ failures
Blood level of marker of inflammation (C Reactive protein)
Delayed healing defined as non hermetic scar
ICU length of stay
Rate of patients with Gastric ulcer
Rate of patients with Digestive bleeding
Rate of patients with Anastomotic leakage
Dose of insulin
Rate of patients with Hypokaliemia (< 4 mmol/l)
Rate of patients with Dysnatremia (<139 mmol/l or > 145 mmol/l)
Rate of patients with Hypocalcemia (<2.2 mmol/l)
Rate of patients with Cardiac events (Atrial fibrillation / cardiac flutter, Acute coronary syndrome or Cardiac failure)

Full Information

First Posted
July 10, 2017
Last Updated
May 28, 2020
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03218553
Brief Title
Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery
Acronym
PACMAN
Official Title
Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery : a Randomized, Multicentre, Double Blind, Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
December 13, 2017 (Actual)
Primary Completion Date
April 16, 2019 (Actual)
Study Completion Date
April 16, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Postoperative complications are major healthcare problems and are associated with a reduced short-term and long-term survival after surgery. Major surgery is associated with a predictable and usually transient Systemic Inflammatory Response (SIRS), depending on the magnitude of the surgical trauma. An excessive SIRS syndrome participates to the development of postoperative organ dysfunction, infection and mortality. Corticosteroids may decrease the postsurgical SIRS in cardiac surgery: in a large multicenter randomized trial, a single intravenous administration of high-dose dexamethasone did not reduce the incidence of a composite endpoint of adverse events but was associated with a reduced incidence of postoperative pulmonary complications and infections and with a reduction in hospital stay. However, a similar study, recently published in the Lancet was negative. Evidences from one meta-analysis, including 11 studies of moderate quality (439 patients in total), suggest that intraoperative administration of corticosteroids during major abdominal surgery decreases postoperative complications, including infectious complications, without significant risk of anastomotic leakage. At present, no large randomized controlled trial has been performed in patients undergoing major non-cardiac surgery. In acute medicine, several lines of evidence have shown that low to moderate doses of corticosteroids decrease the excessive inflammatory response, without inducing immuno suppression. However, despite the widespread use of corticosteroids to reduce postoperative nausea and vomiting and to improve analgesia, concerns continue to be raised about their safety, especially regarding an increased risk of postoperative infection. We hypothesize that the perioperative administration of glucocorticoids would reduce postoperative morbidity after major non-cardiac surgery through dampening of the inflammatory response. Given the number of surgical patients for whom the question applies, the study is of significant clinical importance
Detailed Description
Background : Postoperative complications are major healthcare problems and are associated with a reduced short-term and long-term survival after surgery. Corticosteroids may decrease the postsurgical SIRS in cardiac surgery, but this treatment is not recommended yet. The aim of the current study is to assess the efficiency and the safety of dexamethasone to prevent on postoperative complications. Methods : The PACMAN trial is a multicenter, randomized, controlled, double-blind, two-arms study. 1222 patients undergoing major surgery (duration >90 minutes and one or more risk factor of postoperative complication) are randomized to dexamethasone (0.2mg/kg at the end of the surgery and at day1) or to placebo. The primary outcome is a composite outcome of major postoperative complication during 14 days after the surgery. Analyzes will be conducted, first, on data from the intention-to-treat (ITT) population, second, in the modified intention-to-treat (mITT) population as well as in the per-protocol population. All statistical analyzes will take into account stratified randomization (cancer and type of surgery) and will be adjusted on the center as random effect as. Discussion : The PACMAN trial is the first randomized controlled trial powered to investigate whether perioperative administration of dexamethasone in high risk patients improve outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Non-cardiac Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1222 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Standard cares plus postoperative administrations of glucocorticoid
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Standard cares plus postoperative administrations of placebo
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
Primary Outcome Measure Information:
Title
Composite outcome at least one item among the following:-Postoperative sepsis, severe sepsis, septic shock-Postoperative pulmonary complication: pneumonia, need for invasive and/or noninvasive ventilation for respiratory failure-All-cause mortality
Time Frame
14 days
Secondary Outcome Measure Information:
Title
All cause mortality
Time Frame
28 days
Title
Hospital free days
Time Frame
28 days
Title
Rate of patients with post operative sepsis
Time Frame
28 days
Title
Postoperative intubation rate for respiratory failure
Description
Postoperative respiratory failure requiring invasive ventilation
Time Frame
28 days
Title
Rate of patients with postoperative respiratory failure requiring non-invasive ventilation
Time Frame
28 days
Title
Surgical complications
Description
The Clavien-Dindo classification
Time Frame
28 days
Title
Duration of hospitalization
Time Frame
28 days
Title
Rate of unplanned hospitalization in intensive care unit
Time Frame
28 days
Title
Rate of patients developing postoperative organ failures
Time Frame
28 days
Title
Blood level of marker of inflammation (C Reactive protein)
Time Frame
28 days
Title
Delayed healing defined as non hermetic scar
Time Frame
28 days
Title
ICU length of stay
Time Frame
28 days
Title
Rate of patients with Gastric ulcer
Time Frame
28 days
Title
Rate of patients with Digestive bleeding
Time Frame
28 days
Title
Rate of patients with Anastomotic leakage
Time Frame
28 days
Title
Dose of insulin
Time Frame
3 days
Title
Rate of patients with Hypokaliemia (< 4 mmol/l)
Time Frame
28 days
Title
Rate of patients with Dysnatremia (<139 mmol/l or > 145 mmol/l)
Time Frame
28 days
Title
Rate of patients with Hypocalcemia (<2.2 mmol/l)
Time Frame
28 days
Title
Rate of patients with Cardiac events (Atrial fibrillation / cardiac flutter, Acute coronary syndrome or Cardiac failure)
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 65 years Or Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 50 years and presenting one of the following criteria Presence of a defined risk factor for cardiac or respiratory disease (exercise tolerance equivalent to 6 metabolic equivalents or less) Medical history of stroke Moderate to severe renal impairment (clearance of creatinine ≤ 30 mll/L) Active smoking Averaged observed blood losses over 500 ml Emergency surgery Exclusion Criteria: Pregnant women, Minors, Adults under guardianship or trusteeship Treatment with systemic corticosteroids at a dose > 5 mg.day-1 of equivalent prednisolone in the previous 3 months Patients with chronic renal failure (clearance of creatinine < 10 ml/min) Patients for which death is deemed imminent and inevitable or patients with an underlying disease process with a life expectancy of less than 1 month Patient with preoperative shock (defined by the need for vasoactive drugs before surgery) Acute Pulmonary edema in the last 7 days Active bacterial or viral infection Allergy to the intravenous formulation of dexamethasone Uncontrolled psychotic disorder (acute or chronical)
Facility Information:
Facility Name
CHU Angers
City
Angers
ZIP/Postal Code
49933
Country
France
Facility Name
CHU La Cavale Blanche
City
Brest
ZIP/Postal Code
29609
Country
France
Facility Name
Hôpital Estaing, CHU de Clermont Ferrand
City
Clermont Ferrand
ZIP/Postal Code
63000
Country
France
Facility Name
Hôpital Beaujon
City
Clichy
ZIP/Postal Code
92110
Country
France
Facility Name
CHD Vendée
City
La Roche-sur-Yon
ZIP/Postal Code
85000
Country
France
Facility Name
Centre Hospitalier Du Mans
City
Le Mans
ZIP/Postal Code
72037
Country
France
Facility Name
Hôpital Claude Huriez
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hopital Edouard Herriot
City
Lyon
ZIP/Postal Code
69003
Country
France
Facility Name
Institut Paoli Calmettes
City
Marseille
ZIP/Postal Code
13009
Country
France
Facility Name
Hôpital Timone
City
Marseille
ZIP/Postal Code
13385
Country
France
Facility Name
Hôpital Nord
City
Marseille
ZIP/Postal Code
13975
Country
France
Facility Name
Hôpital Saint-Eloi
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Clinique Jules Verne
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Le Confluent
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Hotel Dieu Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Hôpital Laennec
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
C.R.L.C.C. Nantes Atlantique
City
Nantes
ZIP/Postal Code
44805
Country
France
Facility Name
Hôpital Saint Antoine
City
Paris
ZIP/Postal Code
75000
Country
France
Facility Name
Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand Widal
City
Paris
ZIP/Postal Code
75475
Country
France
Facility Name
CHU Lyon Sud
City
Pierre-Bénite
ZIP/Postal Code
69310
Country
France
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
Ch Quimper
City
Quimper
ZIP/Postal Code
29107
Country
France
Facility Name
Hôpital Pontchaillou
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
CHU de Rouen
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
CHU Saint Etienne
City
Saint-Étienne
ZIP/Postal Code
42055
Country
France
Facility Name
Nouvel Hôpital Civil
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Facility Name
CHU de Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
CH Valenciennes
City
Valenciennes
ZIP/Postal Code
59300
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34078591
Citation
Asehnoune K, Le Moal C, Lebuffe G, Le Penndu M, Josse NC, Boisson M, Lescot T, Faucher M, Jaber S, Godet T, Leone M, Motamed C, David JS, Cinotti R, El Amine Y, Liutkus D, Garot M, Marc A, Le Corre A, Thomasseau A, Jobert A, Flet L, Feuillet F, Pere M, Futier E, Roquilly A; PACMAN study group. Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial. BMJ. 2021 Jun 2;373:n1162. doi: 10.1136/bmj.n1162.
Results Reference
derived
PubMed Identifier
30904834
Citation
Asehnoune K, Futier E, Feuillet F, Roquilly A; PACMAN group. PACMAN trial protocol, Perioperative Administration of Corticotherapy on Morbidity and mortality After Non-cardiac major surgery: a randomised, multicentre, double-blind, superiority study. BMJ Open. 2019 Mar 23;9(3):e021262. doi: 10.1136/bmjopen-2017-021262.
Results Reference
derived

Learn more about this trial

Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery

We'll reach out to this number within 24 hrs